Paroksetyna: interakcje

Avoid administrations of TUDORZA PRESSAIR with other anticholinergic-containing drugs. (etykieta leku Aklidynium, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etykieta leku Amfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Serotonin-norepinephrine reuptake inhibitors (SNRIs) and SSRIs, including Paroxetine HCL CR, can precipitate serotonin syndrome, a potentially life-threatening condition. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Paroxetine HCL CR is contraindicated in patients: Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [See Warnings and Precautions ( 5.2 ), Drug Interactions (7)]. (etykieta leku Paroksetyna, Przeciwwskazania)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Buprenorfina, Interakcje z innymi lekami)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Buprenorfina + nalokson, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Examples paroxetine, fluoxetine, bupropion, quinidine Benzodiazepines and other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. (etykieta leku Butalbital + kwas acetylosalicylowy + kofeina + kodeina, Interakcje z innymi lekami)

Examples: paroxetine, fluoxetine, bupropion, quinidine Benzodiazepines and Other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. (etykieta leku Butalbital + paracetamol + kofeina + kodeina, Interakcje z innymi lekami)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Butorfanol, Środki ostrożności)

Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent. (etykieta leku Chinidyna, Przeciwwskazania)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. (etykieta leku Cytrynian potasu, Przeciwwskazania)

If serotonin syndrome occurs, discontinue dextroamphetamine sulfate and the CYP2D6 inhibitor [see Warnings , Overdosage ]. (etykieta leku Deksamfetamina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Usage of MOTOFEN ® in recommended doses is not likely to cause prominent anticholinergic side effects, but MOTOFEN ® should be avoided in patients in whom anticholinergic drugs are contraindicated. (etykieta leku Difenoksyna + atropina, Ostrzeżenia)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

…(12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone • QTc interval >500 ms or… (etykieta leku Dronedaron, Przeciwwskazania)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Łączenie dziurawca z lekami przeciwdepresyjnymi i innymi lekami serotoninergicznymi zwiększa ryzyko zespołu serotoninowego. (NCCIH, St. John's Wort)

Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding. (etykieta leku Edoksaban, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Examples selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Pimozide and Thioridazine Clinical Impact Paroxetine HCL CR should not be used in patients receiving medications that can prolong QT interval and are metabolized by CYP450 2D6 such as thioridazine or pimozide (see Contraindications and Warnings and Precautions ) Intervention… (etykieta leku Paroksetyna, Interakcje z innymi lekami)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etykieta leku Fentanyl, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

THESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE. (etykieta leku Flumazenil, Ostrzeżenie w ramce)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

• Other Conditions Exacerbated by Anticholinergic Adverse Reactions : Use is not recommended in patients with autonomic neuropathy, hyperthyroidism, cardiac disease, hiatal hernia, etc. (etykieta leku Glikopironium, Ostrzeżenia i środki ostrożności)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etykieta leku Glukagon, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydrokodon, Interakcje z innymi lekami)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydrokodon + chlorfenamina, Interakcje z innymi lekami)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydrokodon + homatropina, Interakcje z innymi lekami)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Hydrokodon + ibuprofen, Środki ostrożności)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Hydrokodon + paracetamol, Środki ostrożności)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydromorfon, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etykieta leku Ipratropium, Interakcje z innymi lekami)

Co-administration with eliglustat is contraindicated in poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. (etykieta leku Itrakonazol, Ostrzeżenie w ramce)

Paroxetine HCL CR is contraindicated in patients: Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [See Warnings and Precautions ( 5.2 ), Drug Interactions (7)]. (etykieta leku Paroksetyna, Przeciwwskazania)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

When possible, avoid concomitant use, with other anticholinergic medications because the risk for anticholinergic toxicity or severe gastrointestinal adverse reactions is increased [see Warnings and Precautions ( 5.7 ), Drug Interactions ( 7.1 )]. (etykieta leku Klozapina, Ostrzeżenia i środki ostrożności)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (etykieta leku Kodeina, Ostrzeżenie w ramce)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Leworfanol, Środki ostrożności)

Paroxetine HCL CR is contraindicated in patients: Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [See Warnings and Precautions ( 5.2 ), Drug Interactions (7)]. (etykieta leku Paroksetyna, Przeciwwskazania)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etykieta leku Lisdeksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

LOREEV XR should not be used in such patients without adequate antidepressant therapy. (etykieta leku Lorazepam, Ostrzeżenia i środki ostrożności)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The concomitant use of METHADOSE with all cytochrome P450 3A4, 2B6, 2C19, 2C9 or 2D6 inhibitors may result in an increase in methadone plasma concentrations, which could cause potentially fatal respiratory depression. (etykieta leku Metadon, Ostrzeżenie w ramce)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (etykieta leku Metaksalon, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etykieta leku Metamfetamina, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, malignant hyperthermia, drug fever, serotonin syndrome, and primary central nervous system pathology. (etykieta leku Metoklopramid, Ostrzeżenia i środki ostrożności)

CYP2D6 Inhibitors Monitor patients closely when the combination use of CYP2D6 inhibitor and metoprolol cannot be avoided. (etykieta leku Metoprolol, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Morfina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (etykieta leku Oksykodon, Interakcje z innymi lekami)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Oksymorfon, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Olicerydyna, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (etykieta leku Paracetamol + kodeina, Ostrzeżenie w ramce)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Pentazocyna + nalokson, Środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Paroxetine HCL CR should not be used in patients receiving medications that can prolong QT interval and are also metabolized by CYP450 2D6,such as thioridazine or pimozide [see Drug Interactions (7),Warnings and Precautions (5.3)]. (etykieta leku Paroksetyna, Przeciwwskazania)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Pokrzyk wilcza jagoda (belladonna) + opium, Interakcje z innymi lekami)

…prolong, or intensify the sedative action of other central-nervous-system depressants, such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should be avoided or administered in reduced dosage to patients receiving promethazine HCl. (etykieta leku Prometazyna, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex, requiring careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. (etykieta leku Prometazyna + kodeina, Ostrzeżenie w ramce)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Paroxetine HCL CR is contraindicated in patients: Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [See Warnings and Precautions ( 5.2 ), Drug Interactions (7)]. (etykieta leku Paroksetyna, Przeciwwskazania)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etykieta leku Remifentanyl, Ostrzeżenia i środki ostrożności)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (etykieta leku Rywastygmina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Examples selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Pimozide and Thioridazine Clinical Impact Paroxetine HCL CR should not be used in patients receiving medications that can prolong QT interval and are metabolized by CYP450 2D6 such as thioridazine or pimozide (see Contraindications and Warnings and Precautions ) Intervention… (etykieta leku Paroksetyna, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Paroxetine HCL CR should not be used in patients receiving medications that can prolong QT interval and are also metabolized by CYP450 2D6,such as thioridazine or pimozide [see Drug Interactions (7),Warnings and Precautions (5.3)]. (etykieta leku Paroksetyna, Przeciwwskazania)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (etykieta leku Tiotropium, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Examples selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Pimozide and Thioridazine Clinical Impact Paroxetine HCL CR should not be used in patients receiving medications that can prolong QT interval and are metabolized by CYP450 2D6 such as thioridazine or pimozide (see Contraindications and Warnings and Precautions ) Intervention… (etykieta leku Paroksetyna, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Avoid administration of Umeclidinium ELLIPTA with other anticholinergic-containing drugs. (etykieta leku Umeklidynium, Interakcje z innymi lekami)

Avoid administration of Umeclidinium and Vilanterol ELLIPTA with other anticholinergic-containing drugs. (etykieta leku Umeklidynium + wilanterol, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Serotonin-norepinephrine reuptake inhibitors (SNRIs) and SSRIs, including Paroxetine HCL CR, can precipitate serotonin syndrome, a potentially life-threatening condition. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Zyprazydon, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

• Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (etykieta leku Adrenalina, Interakcje z innymi lekami)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Table 5: Amiodarone Drug Interactions Concomitant Drug Class/Name Examples Clinical Comment QT Prolonging Drugs class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents Increased risk of Torsade de Pointes. (etykieta leku Amiodaron, Interakcje z innymi lekami)

Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (etykieta leku Anagrelid, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (etykieta leku Arformoterol, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. (etykieta leku Artykaina + adrenalina, Interakcje z innymi lekami)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Arypiprazol, Ostrzeżenia i środki ostrożności)

Paroxetine (CYP2D6 substrate and inhibitor): Reduce paroxetine by half when used in combination with SAPHRIS. (etykieta leku Asenapina, Interakcje z innymi lekami)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (etykieta leku Brekspiprazol, Ostrzeżenia i środki ostrożności)

Caution is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (etykieta leku Brymonidyna, Interakcje z innymi lekami)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (etykieta leku Brymonidyna + tymolol, Interakcje z innymi lekami)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etykieta leku Budezonid + formoterol, Interakcje z innymi lekami)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (etykieta leku Bupiwakaina, Ostrzeżenia i środki ostrożności)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (etykieta leku Bupiwakaina + adrenalina, Ostrzeżenia i środki ostrożności)

Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). (etykieta leku Bupropion, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Although clinical drug interaction studies have not been performed, antimalarial doses (greater than or equal to 600 mg) of quinine may inhibit the metabolism of other drugs that are CYP2D6 substrates (e.g., flecainide, debrisoquine, dextromethorphan, metoprolol, paroxetine ). (etykieta leku Chinina, Interakcje z innymi lekami)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (etykieta leku Chloroprokaina, Środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

…apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline, and metronidazole, thereby delaying elimination and increasing blood levels of these drugs. (etykieta leku Cymetydyna, Interakcje z innymi lekami)

Dose adjustments may be required for concomitant medications that are predominantly metabolized by CYP2D6 (e.g., desipramine, metoprolol, and carvedilol) and particularly those with a narrow therapeutic index (e.g., flecainide and most tricyclic antidepressants) [see Clinical Pharmacology ( 12.3 )] . (etykieta leku Cynakalcet, Interakcje z innymi lekami)

…syndrome, uncorrected electrolyte imbalance, such as hypokalemia or hypomagnesemia and cardiac disease, such as heart failure, myocardial infarction, or bradycardia), and patients receiving Class IA antiarrhythmic agents (quinidine, procainamide), or Class III antiarrhythmic agents (amiodarone, sotalol), tricyclic antidepressants, macrolides, and antipsychotics. (etykieta leku Cyprofloksacyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Antidepressants : Selective Serotonin Reuptake Inhibitors (SSRIs): paroxetine, sertraline ↓ paroxetine ↓ sertraline If either sertraline or paroxetine is initiated in patients receiving PREZISTA/ritonavir, dose titrating the SSRI based on a clinical assessment of antidepressant response is recommended. (etykieta leku Darunawir, Interakcje z innymi lekami)

Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs): e.g. paroxetine, sertraline SSRIs: effects unknown When co-administering with SSRIs, TCAs, or trazodone, careful dose titration of the antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitoring for antidepressant response are recommended. (etykieta leku Darunawir + kobicystat, Interakcje z innymi lekami)

CYP2D6 Inhibitors No dosing adjustments are recommended in the presence of CYP2D6 inhibitors (for example, paroxetine, fluoxetine, quinidine and duloxetine) [see Clinical Pharmacology (12.3)] . (etykieta leku Daryfenacyna, Interakcje z innymi lekami)

The intravenous administration of anticholinergic agents (e.g., glycopyrrolate, atropine) should be considered to modify vagal tone. (etykieta leku Deksmedetomidyna, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

…that may Increase Risk of Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin… (etykieta leku Desmopresyna, Interakcje z innymi lekami)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Deutetrabenazyna, Ostrzeżenia i środki ostrożności)

…be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of Valium, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. (etykieta leku Diazepam, Interakcje z innymi lekami)

Anticholinergic agents: may affect the gastrointestinal absorption of various drugs; may also increase certain actions or side effects of other anticholinergic drugs (7) (etykieta leku Dicykloweryna, Interakcje z innymi lekami)

Clinical presentations vary in terms of which toxicity (anticholinergic vs. opioid) will present first or predominate; non-specific findings have been reported and include symptoms such as drowsiness (see OVERDOSAGE ). (etykieta leku Difenoksylat + atropina, Ostrzeżenia)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously co-administered with dofetilide as they can potentially increase dofetilide levels. (etykieta leku Dofetylid, Interakcje z innymi lekami)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (etykieta leku Dorzolamid + tymolol, Interakcje z innymi lekami)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (etykieta leku Dronabinol, Ostrzeżenia i środki ostrożności)

Possible pharmacodynamic interactions can occur between droperidol and potentially arrhythmogenic agents such as class I or III antiarrhythmics, antihistamines that prolong the QT interval, antimalarials, calcium channel blockers, neuroleptics that prolong the QT interval, and antidepressants. (etykieta leku Droperydol, Interakcje z innymi lekami)

Use caution in combination with moderate CYP3A4 inhibitors (e.g., erythromycin) or strong (e.g., paroxetine) or moderate CYP2D6 inhibitors, a combination of both CYP3A4 and CYP2D6 inhibitors, or known poor metabolizers of CYP2D6. (etykieta leku Dutasteryd + tamsulosyna, Ostrzeżenia i środki ostrożności)

Antidepressant: Bupropion Sertraline ↓ bupropion * ↓ sertraline * Increases in bupropion dosage should be guided by clinical response. (etykieta leku Efawirenz, Interakcje z innymi lekami)

Antidepressants: Bupropion ↓ bupropion Increases in bupropion dosage should be guided by clinical response. (etykieta leku Efawirenz + lamiwudyna + tenofowir, Interakcje z innymi lekami)

Examples: alosetron, anticholinergics, opioids Table 3: Established and Other Potentially Clinically Relevant Interactions Affecting Drugs Co-Administered with VIBERZI OATP1B1 and BCRP Substrate Clinical Impact: VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates. (etykieta leku Eluksadolina, Interakcje z innymi lekami)

Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs) e.g., paroxetine Tricyclic Antidepressants (TCAs) e.g., amitriptyline desipramine imipramine nortriptyline bupropion trazodone ↑ SSRIs (except sertraline) ↑ TCAs ↑ trazodone Careful dosage titration of the antidepressant and monitoring for antidepressant response are recommended when coadministered… (etykieta leku Elwitegrawir + kobicystat + emtrycytabina + tenofowir, Interakcje z innymi lekami)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (etykieta leku Eszopiklon, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (etykieta leku Fenylefryna, Interakcje z innymi lekami)

…Increased and decreased PT/INR responses have been reported when phenytoin is coadministered with warfarin Other Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D Drugs whose level is decreased by phenytoin Anticoagulants Apixaban, dabigatran, edoxaban, rivaroxaban Antiepileptic… (etykieta leku Fenytoina, Interakcje z innymi lekami)

Urinary Retention in Adult Patients With Bladder Outlet Obstruction The use of Toviaz, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction, including patients with urinary retention, may result in further urinary retention and kidney injury. (etykieta leku Fezoterodyna, Ostrzeżenia i środki ostrożności)

Acute cardiac arrest may be possible during treatment with tricyclic antidepressants; therefore, Anticholium should only be considered as an antidote for this indication while the patient has continuous ECG monitoring. (etykieta leku Fizostygmina, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (etykieta leku Flufenazyna, Ostrzeżenia)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etykieta leku Flutykazon + salmeterol, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

• MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system. (etykieta leku Formoterol, Interakcje z innymi lekami)

Fosamprenavir/Ritonavir Clinical Impact Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. (etykieta leku Paroksetyna, Interakcje z innymi lekami)

Other Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D Drugs whose level is decreased by phenytoin Anticoagulants Apixaban, dabigatran, edoxaban, rivaroxaban Antiepileptic drugs The effect of phenytoin on phenobarbital, valproic acid and sodium valproate serum levels… (etykieta leku Fosfenytoina, Interakcje z innymi lekami)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval, such as class IA or class III antiarrhythmic medications, tricyclic antidepressants, macrolides, and antipsychotics [see Warnings and Precautions ( 5.2 )] . (etykieta leku Fosfomycyna, Interakcje z innymi lekami)

…prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic antidepressants, and certain macrolides and fluoroquinolones. (etykieta leku Foskarnet, Interakcje z innymi lekami)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etykieta leku Gefitynib, Interakcje z innymi lekami)

Increases in QTc have been observed when haloperidol was given with a combination of the metabolic inhibitors ketoconazole (400 mg/day) and paroxetine (20 mg/day). (etykieta leku Haloperydol, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Coadministration of paroxetine with iloperidone resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6- fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half [see Clinical Pharmacology (12.3 , 12.5) ] . (etykieta leku Iloperydon, Interakcje z innymi lekami)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Because of its anticholinergic effects, XEOMIN should be used with caution in patients at risk of developing narrow angle glaucoma. (etykieta leku Inkobotulinumtoksyna A, Ostrzeżenia i środki ostrożności)

Caution is, therefore, advised in the co-administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution with other drugs having anticholinergic properties. β-adrenergic agents Caution is advised in the co-administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution and other sympathomimetic agents due to the increased risk… (etykieta leku Ipratropium + salbutamol, Interakcje z innymi lekami)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (etykieta leku Izoprenalina, Interakcje z innymi lekami)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (etykieta leku Karbidopa, Ostrzeżenia)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (etykieta leku Karbidopa + lewodopa + entakapon, Interakcje z innymi lekami)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use VRAYLAR with caution in patient who may experience these conditions. (etykieta leku Kariprazyna, Ostrzeżenia i środki ostrożności)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (etykieta leku Karwedilol, Interakcje z innymi lekami)

Since the sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously. (etykieta leku Karyzoprodol, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (etykieta leku Klonazepam, Interakcje z innymi lekami)

Tricyclic antidepressants Clinical Implication Concomitant use of tricyclic antidepressants with clonidine can increase blood pressure and may counteract the hypotensive effects of clonidine. (etykieta leku Klonidyna, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (etykieta leku Klorazepan, Interakcje z innymi lekami)

Sympathomimetics, postganglionic blocking agents, and tricyclic antidepressants: Concomitant administration may increase the risk of cardiovascular adverse reactions. (etykieta leku Kokaina, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

• Anticholinergic (antimuscarinic) Effects: Use with caution with other anticholinergic drugs and in patients with urinary retention, prostatic hypertrophy, or constipation (5.20) (etykieta leku Kwetiapina, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Lemboreksant, Ostrzeżenia i środki ostrożności)

Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants : May potentiate effect of albuterol on the cardiovascular system. (etykieta leku Lewosalbutamol, Interakcje z innymi lekami)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (etykieta leku Lewotyroksyna, Interakcje z innymi lekami)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (etykieta leku Lidokaina, Interakcje z innymi lekami)

…Adverse Reactions Due to Drug Interactions with FLAVALTA Risk of Severe, Persistent Hypertension Due to Drug Interactions Between FLAVALTA and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of FLAVALTA (containing a vasoconstrictor, epinephrine) in patients receiving monoamine oxidase inhibitors (MAOI), or tricyclic antidepressants may result… (etykieta leku Lidokaina + adrenalina, Ostrzeżenia i środki ostrożności)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and liothyronine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (etykieta leku Liotyronina, Interakcje z innymi lekami)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (etykieta leku Lofeksydyna, Interakcje z innymi lekami)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (etykieta leku Loksapina, Ostrzeżenia)

Fosamprenavir/Ritonavir Clinical Impact Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. (etykieta leku Paroksetyna, Interakcje z innymi lekami)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (etykieta leku Lumateperon, Ostrzeżenia i środki ostrożności)

Activation of Mania/Hypomania Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. (etykieta leku Lurazydon, Ostrzeżenia i środki ostrożności)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (etykieta leku Meflochina, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (etykieta leku Mepiwakaina, Ostrzeżenia)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (etykieta leku Metyloskopolamina, Interakcje z innymi lekami)

• Urinary Retention in Patients With Bladder Outlet Obstruction and in Patients Taking Muscarinic Antagonist Drugs for Overactive Bladder : Administer with caution in these patients because of risk of urinary retention. (etykieta leku Mirabegron, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (etykieta leku Moksyfloksacyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (etykieta leku Nalbufina, Interakcje z innymi lekami)

Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of antidepressants, (e.g., selective serotonin reuptake inhibitors and many tricyclics), antipsychotics (e.g., haloperidol, risperidone and thioridazine), beta-blockers (e.g., metoprolol) and Type 1C antiarrhythmics (e.g., propafenone and flecainide). (etykieta leku Naltrekson + bupropion, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Use with CYP2D6 Inhibitors Nebivolol exposure increases with inhibition of CYP2D6 [see Drug Interactions ( 7 ) ] . (etykieta leku Nebiwolol, Ostrzeżenia i środki ostrożności)

An anticholinergic agent, (e.g., atropine sulfate or glycopyrrolate) should be administered prior to Neostigmine Methylsulfate Injection administration to lessen the risk of bradycardia [ see Dosage and Administration ( 2.4 ) ]. (etykieta leku Neostygmina, Ostrzeżenia i środki ostrożności)

Fosamprenavir/Ritonavir Clinical Impact Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. (etykieta leku Paroksetyna, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

The concurrent use of Xyrem with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and… (etykieta leku Oksybat sodu, Ostrzeżenia i środki ostrożności)

Oxybutynin chloride extended-release tablets, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis and intestinal atony. (etykieta leku Oksybutynina, Ostrzeżenia i środki ostrożności)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etykieta leku Oksykodon + paracetamol, Interakcje z innymi lekami)

Anticholinergic (antimuscarinic) Effects: Use with caution with other anticholinergic drugs and in patients with urinary retention, prostatic hypertrophy, constipation, paralytic ileus or related conditions. (etykieta leku Olanzapina, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Anticholinergic Drugs Use of anticholinergic drugs after administration of BOTOX may potentiate systemic anticholinergic effects. (etykieta leku Onabotulinumtoksyna A, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (etykieta leku Perfenazyna, Ostrzeżenia)

These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium). (etykieta leku Pilokarpina, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (etykieta leku Pirydostygmina, Ostrzeżenia i środki ostrożności)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (etykieta leku Pitolisant, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Anticholinergic drugs administered concurrently with PA may produce additive antivagal effects on A-V nodal conduction, although this is not as well documented for PA as for quinidine. (etykieta leku Prokainamid, Interakcje z innymi lekami)

Drugs that inhibit these CYP pathways (such as desipramine, paroxetine, ritonavir, sertraline for CYP2D6; ketoconazole, erythromycin, saquinavir, and grapefruit juice for CYP3A4; and amiodarone and tobacco smoke for CYP1A2) can be expected to cause increased plasma levels of propafenone. (etykieta leku Propafenon, Ostrzeżenia i środki ostrożności)

The intravenous administration of anticholinergic agents (e.g., atropine or glycopyrrolate) should be considered to modify potential increases in vagal tone due to concomitant agents (e.g., succinylcholine) or surgical stimuli. (etykieta leku Propofol, Ostrzeżenia i środki ostrożności)

Impact of Other Drugs on Propranolol CYP2D6, CYP1A2 and CYP2C19 Inhibitors: CYP2D6 inhibitors (e.g. bupropion, fluoxetine, paroxetine, quinidine), CYP1A2 inhibitors (e.g., ciprofloxacin, enoxamine, fluvoxamine) and CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine, ticlopidine) increase exposure to propranolol when co-administered with INNOPRAN XL. (etykieta leku Propranolol, Interakcje z innymi lekami)

…Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (etykieta leku Prylokaina + adrenalina, Interakcje z innymi lekami)

Effects of Other Drugs on the Pharmacokinetics of Primaquine Strong CYP2D6 Inhibitors Published clinical and non-clinical reports indicate reduced CYP2D6 activity may decrease the formation of active metabolites of primaquine, which may reduce antimalarial efficacy of Primaquine phosphate Tablets (see CLINICAL PHARMACOLOGY, Pharmacogenomics ). (etykieta leku Prymachina, Interakcje z innymi lekami)

Drugs transported by P-gp (e.g., digoxin), or drugs metabolized by CYP2D6 (e.g., tricyclic antidepressants) may need reduced doses when used with ASPRUZYO Sprinkle. (etykieta leku Ranolazyna, Interakcje z innymi lekami)

…5-HT 3 Receptor Antagonists Ondansetron Decrease exposure Statins Metabolized by CYP3A4 Simvastatin Decrease exposure Thiazolidinediones Rosiglitazone Decrease AUC by 66% Tricyclic Antidepressants Nortriptyline A tuberculosis treatment regimen including rifampin (600 mg/day), isoniazid (300 mg/day), pyrazinamide (500 mg 3× per day), and pyridoxine (25 mg) was… (etykieta leku Ryfampicyna, Interakcje z innymi lekami)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (etykieta leku Ryfapentyna, Interakcje z innymi lekami)

Fluoxetine and paroxetine increase plasma concentrations of risperidone. (etykieta leku Rysperydon, Interakcje z innymi lekami)

Fosamprenavir/Ritonavir Clinical Impact Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. (etykieta leku Paroksetyna, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etykieta leku Salbutamol, Interakcje z innymi lekami)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etykieta leku Salmeterol, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (etykieta leku Sewofluran, Ostrzeżenia)

• Gastrointestinal and Urinary Disorders : Consider more frequent monitoring during treatment in patients suspected of having intestinal obstruction; patients with pyloric obstruction, patients with impeded urine flow or receiving other anticholinergic drugs. (etykieta leku Skopolamina, Ostrzeżenia i środki ostrożności)

Urinary Retention The use of Solifenacin succinate tablets, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction including patients with urinary retention, may result in further urinary retention and kidney injury. (etykieta leku Solifenacyna, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Monitor for hemodynamic changes and administer anticholinergic agents such as atropine if clinically significant bradycardia is observed. (etykieta leku Sugammadeks, Ostrzeżenia i środki ostrożności)

Pretreatment with anticholinergic agents (e.g., atropine) may reduce the occurrence of bradyarrhythmias. (etykieta leku Suksametonium, Ostrzeżenia i środki ostrożności)

The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. (etykieta leku Sulfametoksazol + trimetoprim, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (etykieta leku Suworeksant, Ostrzeżenia i środki ostrożności)

Reduction of Efficacy of Tamoxifen Some studies have shown that the efficacy of tamoxifen, as measured by the risk of breast cancer relapse/mortality, may be reduced with concomitant use of paroxetine as a result of paroxetine’s irreversible inhibition of CYP2D6 and lower blood levels of tamoxifen [see Drug Interactions ( 7.1 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (etykieta leku Tamsulosyna, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

The benzodiazepines, including temazepam, produce additive CNS-depressant effects when co-administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. (etykieta leku Temazepam, Interakcje z innymi lekami)

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (etykieta leku Terbutalina, Środki ostrożności)

• Do not exceed 50 mg/day and the maximum single dose should not exceed 25 mg if administered in conjunction with a strong CYP2D6 inhibitor (e.g., fluoxetine, paroxetine). (etykieta leku Tetrabenazyna, Ostrzeżenia i środki ostrożności)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (etykieta leku Tiotyksen, Ostrzeżenia)

Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (etykieta leku Toksyna botulinowa typu A, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Caution should be used when topiramate extended-release capsules are prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity. (etykieta leku Topiramat, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

…quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron). (etykieta leku Toremifen, Interakcje z innymi lekami)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (etykieta leku Trifluoperazyna, Ostrzeżenia)

The recent use of other drugs that cause CNS depression or EPS symptoms (e.g., alcohol, sedatives, hypnotics, opiates, anxiolytics, antipsychotics, and anticholinergics) may also increase the risk for these serious CNS reactions [see Warnings and Precautions ( 5.1 , 5.5 )] . (etykieta leku Trimetobenzamid, Ostrzeżenia i środki ostrożności)

Trospium chloride extended-release capsules, like other antimuscarinic agents, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis, intestinal atony and myasthenia gravis. (etykieta leku Trospium, Ostrzeżenia i środki ostrożności)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine) and timolol. (etykieta leku Tymolol, Interakcje z innymi lekami)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

The CNS depressant effects of Zanaflex with alcohol and other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants) may be additive [see Drug Interactions ( 7.4 )] . (etykieta leku Tyzanidyna, Ostrzeżenia i środki ostrożności)

For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

For patients taking warfarin, carefully monitor the international normalized ratio. (etykieta leku Paroksetyna, Ostrzeżenia i środki ostrożności)

Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (etykieta leku Wazopresyna, Interakcje z innymi lekami)

Urinary Retention : Monitor for urinary retention, especially in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for OAB, in whom the risk of urinary retention may be greater. (etykieta leku Wibegron, Ostrzeżenia i środki ostrożności)

Paroxetine: Coadministration of a single dose of zaleplon 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance. (etykieta leku Zaleplon, Interakcje z innymi lekami)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use [see Drug Interactions (7.1) ] . (etykieta leku Zolpidem, Ostrzeżenia i środki ostrożności)

Caution should be used when ZONISADE is prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, carbonic anhydrase inhibitors and drugs with anticholinergic activity. (etykieta leku Zonisamid, Ostrzeżenia i środki ostrożności)

Antidepressants: tricyclic antidepressants ↑ tricyclic antidepressants Coadministration with REYATAZ has the potential to produce serious and/or life-threatening adverse events and has not been studied. (etykieta leku Atazanawir, Interakcje z innymi lekami)

When benztropine mesylate is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly. (etykieta leku Benzatropina, Ostrzeżenia)

Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly. (etykieta leku Cewimelina, Interakcje z innymi lekami)

As with other anticholinergic drugs, clidinium may cause suppression of lactation. (etykieta leku Chlordiazepoksyd + klidynium, Interakcje z innymi lekami)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (etykieta leku Diwalproeks (walproinian), Interakcje z innymi lekami)

Cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Donepezyl, Interakcje z innymi lekami)

Examples propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, risperidone. (etykieta leku Paroksetyna, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

…quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone,… (etykieta leku Hydroksyzyna, Środki ostrożności)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (etykieta leku Kwas walproinowy, Interakcje z innymi lekami)

These included patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs. (etykieta leku Leuprorelina, Ostrzeżenia i środki ostrożności)

These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products. (etykieta leku Lowastatyna, Ostrzeżenia)

• CYP2D6 inhibitors: As meclizine is metabolized by CYP2D6, there is a potential for drug-drug interactions between meclizine hydrochloride and CYP2D6 inhibitors ( 7.2 ). (etykieta leku Meklozyna, Interakcje z innymi lekami)

NAMZARIC may interfere with anticholinergic medications. (etykieta leku Memantyna + donepezyl, Interakcje z innymi lekami)

Appropriate care is advised when prescribing ERZOFRI to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration. (etykieta leku Paliperydon, Ostrzeżenia i środki ostrożności)

Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (etykieta leku Terbinafina, Interakcje z innymi lekami)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (etykieta leku Tiagabina, Ostrzeżenia)

It is difficult to determine if Tolcapone tablets played a role in the pathogenesis of these events because these patients received several concomitant medications affecting the central nervous system such as monoaminergic (i.e., MAO-I, tricyclic and selective serotonin reuptake inhibitors) and anticholinergic agents. (etykieta leku Tolkapon, Środki ostrożności)

Examples propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, risperidone. (etykieta leku Paroksetyna, Interakcje z innymi lekami)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (etykieta leku Triheksyfenidyl, Interakcje z innymi lekami)

…changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .] 7.2 Fluoxetine In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes… (etykieta leku Desloratadyna, Interakcje z innymi lekami)

No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa and dopa-decarboxylase inhibitor. (etykieta leku Entakapon, Środki ostrożności)

…to the drugs included in Table 4, the interaction between Etravirine and the following drugs were evaluated in clinical studies and no dose adjustment is needed for either drug [see Clinical Pharmacology (12.3) ] : didanosine, enfuvirtide (ENF), ethinylestradiol/norethindrone, omeprazole, paroxetine, raltegravir, ranitidine, and tenofovir disoproxil fumarate. (etykieta leku Etrawiryna, Interakcje z innymi lekami)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (etykieta leku Ropinirol, Interakcje z innymi lekami)